Blog


Over the past decade, pharmaceutical firms have been giving oncologists the choice to combine several drugs used in cancer treatment in order to battle even the most resistant of cancer cells. This move has been proven successful in some types of cancer, prompting pharmaceutical manufacturers to supply consistent, quality-controlled active pharmaceutical ingredients (API’s), such as[…]

Read More

In 2009 a new anti-cancer drug, Everolimus, was approved in the US and Europe specifically for use in patients with advanced kidney cancer who were unresponsive to the standard chemotherapy regimen. As a kinase inhibitor, Everolimus effectively inhibits cancer cells from dividing. Since then, the use of Everolimus has extended to treatment of subependymal giant[…]

Read More

Although not brand new, Toremifene has been found to be as effective as Tamoxifen, in breast cancer, as a selective estrogen receptor modulator (SERM) with the added advantage of better patient tolerability and lesser adverse effects. Several drugs for this specific type of cancer have been developed but only a handful has made it to[…]

Read More

Elacridar, an ABCB1 modulator acting as a drug transporter, has been proven to have beneficial effects on the resistance of cancer cells to standard chemotherapeutic agents. This unique delivery system makes resistant cancers more susceptible to standard chemotherapeutic regimen. A study done by Ho Lun Wong et al showed beneficial results when Elacridar was used[…]

Read More

Studies with Adalimumab and a TNF-α blockade shows promising results for Adalimumab therapy for joint pain. Joint pains have inflicted thousands of people worldwide. Age is a non-modifiable risk factor when it comes to degenerative bone disease. However, certain autoimmune joint diseases affect the young population as well. Juvenile idiopathic arthritis, ankylosing spondylitis, rheumatoid arthritis[…]

Read More

For several years now, LGM Pharma has been a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged a longstanding partnership with GlaxoSmithKline, Eli[…]

Read More

A study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell[…]

Read More

Vilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year.  The drug will be available in 10 mg, 20 mg and 40 mg dosage forms. Major Depressive Disorder is commonly known as major depression. Unlike bipolar disorder, it is characterized by one extreme mood i.e. depressed mood.[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service